BiotechTube

Azacitidine + Iadademstat + Venetoclax

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acute Myeloid Leukemia

Conditions

Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia

Trial Timeline

Aug 22, 2024 → May 29, 2026

NCT ID
NCT06357182

About Azacitidine + Iadademstat + Venetoclax

Azacitidine + Iadademstat + Venetoclax is a phase 1 stage product being developed by Oryzon Genomics for Acute Myeloid Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06357182. Target conditions include Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06357182Phase 1Recruiting

Competing Products

20 competing products in Acute Myeloid Leukemia

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
25
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
44
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
TRV130TrevenaPhase 3
69
TRV130 + Morphine + PlaceboTrevenaPhase 2
44
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
SPT-07A injectionSinopharmPhase 3
76
PRGN-3006 T CellsPrecigenPhase 1
28
BisantreneRace OncologyPhase 2
44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
25
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
44
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
33
ZN-d5Zentalis PharmaceuticalsPhase 1
25
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
25
LY2523355Eli LillyPhase 1
33
TomivosertibeFFECTOR TherapeuticsPhase 1
25
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
77

Other Products from Oryzon Genomics

Iadademstat + PaclitaxelPhase 2
44
vafidemstat + PlaceboPhase 2
44
ORY-2001 Low dose + ORY-2001 High dose + PlaceboPhase 2
44
Iadademstat + AtezolizumabPhase 1
25
Iadademstat + Gilteritinib Oral TabletPhase 1
25